Form 4: Sana Biotechnology Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Robert Nelsen was granted 90,000 stock options in Sana Biotechnology, Inc. with an exercise price of $2.96.
Summary
- Director Robert Nelsen received a grant of 90,000 stock options for Sana Biotechnology, Inc. common stock.
- The options have an exercise price of $2.96 per share.
- The grant date for the transaction was June 4, 2026.
- The options are scheduled to vest in full on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- The grant aligns the director's long-term interests with those of the shareholders through equity-based compensation.
Negatives
- The issuance of new stock options results in potential future dilution for existing shareholders.
Risks
- The value of the options is dependent on the future performance of the company's stock price relative to the $2.96 exercise price.
Future Outlook
The options vest in one year, contingent upon the director's continued service to the company.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term commitment and alignment with corporate governance standards.
Comparison to Industry Standards
- The use of time-based vesting for director compensation is consistent with standard corporate governance practices for NASDAQ-listed biotechnology firms.
- The exercise price reflects the market valuation at the time of the grant, adhering to standard fair market value requirements.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of attorneys-in-fact for SEC filing purposes. | 2025-11-04 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 4, 2027, or the 2027 annual meeting date.
Key Dates
| Date | Description |
|---|---|
| 2025-11-04 | Date of Power of Attorney execution. |
| 2026-06-04 | Date of the stock option grant transaction. |
| 2026-06-05 | Date of filing. |
| 2027-06-04 | Vesting date for the stock options. |
| 2036-06-03 | Expiration date of the stock options. |
Keywords
Sana Biotechnology, SANA, Director, Stock Options, Form 4, Insider Trading, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.